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During peritoneal dialysis (PD), constant exposure of mesothelial cells to bioincompatible PD solutions results in the denudation
of the mesothelial monolayer and impairment of mesothelial cell function. Hyaluronan, a major component of extracellular
matrices, is synthesized by mesothelial cells and contributes to remesothelialization, maintenance of cell phenotype, and tissue
remodeling and provides structural support to the peritoneal membrane. Chronic peritoneal inflammation is observed in long-
term PD patients and is associated with increased hyaluronan synthesis. During inflammation, depolymerization of hyaluronan
may occur with the generation of hyaluronan fragments. In contrast to native hyaluronan which offers a protective role to the
peritoneum, hyaluronan fragments exacerbate inflammatory and fibrotic processes and therefore assist in the destruction of the
tissue. This paper will discuss the contribution of mesothelial cells to peritoneal membrane alterations that are induced by PD and
the putative role of hyaluronan in these processes.
1. Introduction
Peritoneal dialysis (PD) is an effective form of renal replace-
ment therapy that is currently used by approximately 11%
of the total global dialysis population. Although PD has
greatly improved the quality of life in renal patients, a major
disadvantage of this treatment is that PD solutions are bio-
incompatible since they contain elevated concentrations of
glucose to provide the osmotic drive, a low pH to prevent
glucose caramelization during heat sterilization and lactate
to correct metabolic acidosis. Heat sterilization of glucose-
based PD solutions and storage can give rise to the formation
of glucose degradation products (GDPs). Besides their direct
toxic effect on mesothelial cells [1], GDPs promote the
formation of advanced glycation end products [2]. These
constituents have been shown to provoke peritoneal inflam-
mation and injury in mesothelial cells, resulting in structural
changes in the peritoneal membrane and progressive loss
of peritoneal functions [3–5]. Studies have demonstrated
that many patients on long-term PD exhibit reduplication
of the basal lamina, increased synthesis and deposition of
matrix proteins within the submesothelium, and progressive
subendothelial hyalinization, with narrowing or obliteration
of the vascular lumen [6, 7]. These structural changes are
exacerbated by episodes of peritonitis and are associated with
a loss of ultrafiltration and solute clearance that leads to
technique failure and unfavorable clinical outcomes. Specifi-
cally how these changes in the peritoneal membrane are
regulated remains to be fully elucidated.
Hyaluronan is a large glycosaminoglycan that is con-
stitutively synthesized by mesothelial cells. We and others
have demonstrated that hyaluronan plays a crucial role
in the maintenance of mesothelial cell morphology and
remesothelialization [8, 9]. While the mechanisms through
which hyaluronan participates in peritoneal homeostasis
and pathological processes are being investigated, there is
accumulating data to show that the hyaluronan molecule
can exert either protective or potentially destructive effects
depending on its molecular weight, local concentration, and
tissue distribution. This paper will focus on the putative role
2 Journal of Biomedicine and Biotechnology
of hyaluronan in peritoneal homeostasis and how alterations
in hyaluronan synthesis induced by PD can contribute to
peritoneal inflammation, EMT, and fibrosis.
2. Peritoneal Mesothelial Cells
The peritoneal membrane consists of a monolayer of meso-
thelial cells underneath which contains the submesothelium,
fibroblasts, collagen fibrils, and capillaries [10]. Peritoneal
mesothelial cells are specialized epithelial cells that line the
peritoneal cavity. Although previously thought to function
solely as a lubricating, nonadhesive surface to facilitate intra-
coelomic movement, there is now compelling evidence to
demonstrate that peritoneal mesothelial cells are not passive
cells but play critical roles in peritoneal homeostasis, main-
tenance of peritoneal membrane integrity, fluid, and solute
transport, peritoneal inflammation, and wound healing.
Mesothelial cells regulate peritoneal inflammation and tissue
remodeling by virtue of their ability to synthesize a plethora
of cytokines, growth factors, and matrix proteins [11–14].
Mesothelial cells also synthesize glycosaminoglycans and
proteoglycans such as hyaluronan, decorin, syndecan-1, and
perlecan that endow the mesothelium with a protective
glycocalyx and selective permeability property [15–24].
Although mesothelial cells are derived from the meso-
derm, they possess many features of epithelial cells that
include a polygonal, cobblestone morphology with surface
microvilli, are situated on a basement membrane, express
cytokeratin, and have the ability to form a polarized mono-
layer that permits translocation of molecules to either the
apical or basolateral aspect of the cells [25–29]. Cell polarity
is essential to maintain normal mesothelial cell function and
occurs upon cell-cell contact. The precise distribution of
proteins to the apical or basolateral aspect of the cell is critical
for cell signaling and interaction with their microenviron-
ment. With regard to their mesenchymal characteristics,
mesothelial cells can express vimentin, desmin, and α-
smoothmuscle actin, the latter induced during cell activation
[25, 29–31]. Mesothelial cells are connected by intercellular
junctions (tight junctions, gap junctions, adherens junctions,
and desmosomes) that contribute to the establishment
and maintenance of a continuous mesothelial monolayer
[32]. Mesothelial cells have been shown to express ZO-
1, occluding, and claudin-1 [33, 34]. Reduced expression
of adherens junctions during pathologic conditions or
inflammatory processes is associated with a collapse of cell-
cell communication and cell-matrix interaction resulting in
the denudation of the mesothelium, a process that is often
observed during PD [33, 34].
Since an in-depth discussion onmesothelial cell structure
and function is beyond the scope of this paper, the reader is
referred to the related reviews [26, 27, 35–37].
3. Hyaluronan
Hyaluronan is a negatively charged, linear polysaccharide
that is widely distributed in epithelial, connective, and
neural tissues [38, 39]. Unlike other glycosaminoglycans, it
is neither sulfated nor is it attached to a protein core. It is
composed of repeating disaccharide units of D-glucuronic
acid and N-acetyl-D-glucosamine and is synthesized on the
inner surface of plasma membranes by uridine diphosphate
glucose dehydrogenase and one of three related hyaluronan
synthases (HAS), namely, HAS I, II, or III [40]. These
isoenzymes have a 55–70% homology, and HAS II is critical
for animal survival [41]. HAS I is the least active of the HAS
isoenzymes and together with HAS II controls the synthesis
of highmolecular weight (HMW) or native hyaluronan. HAS
II is more active than HAS I, and its upregulation is impli-
cated in wound healing, inflammation, and tissue growth.
Of the 3 isozymes, HAS III is the most active and drives the
synthesis of lowmolecular weight (LMW) hyaluronan. Given
that HAS I, II, and III expressions are differentially regulated
by cytokines and growth factors [42], it is plausible to suggest
that depending on the inciting factor, one or more HAS
isoforms may be upregulated to induce hyaluronan synthesis
of different molecular weights and abundance.
Under physiologic conditions, hyaluronan is synthesized
as a macromolecule with a molecular weight in excess of
106 Da [43]. Following its synthesis, hyaluronan is directed
to the cell surface where it interacts with its receptor
CD44 or it is assembled into the pericellular matrix (gly-
cocalyx) or extracellular matrix (ECM). The regulation of
hyaluronan translocation to the different compartments
of the cell is currently unknown, but it is possible that
mechanisms used to export other polysaccharides may
be involved such as the adenosine-5′-triphosphate-binding
cassette system. Despite its simple structure, hyaluronan is
a multifaceted molecule that contributes to the structural
integrity of tissues, maintains water balance, assists in the
distribution and transport of plasma proteins, promotes
cell quiescent, decreases fibrotic mediators, and possesses
anti-inflammatory properties [44–46]. Due to its ability to
regulate cell proliferation, migration and phenotype, and
cell-cell communication, hyaluronan also plays a pivotal role
in metastasis and tumorigenesis [47–49]. Hyaluronan can
influence physiologic cell behavior through three mecha-
nisms. Firstly, hyaluronan can form tertiary structures in
aqueous solutions and interact with water molecules result-
ing in the production of a hydrated environment with high
viscosity and elasticity that allows cells to divide and migrate
[50]. Secondly, hyaluronan contributes to the assembly and
structural integrity of pericellular matrices, which influence
cell shape during cell division, movement, and morphogen-
esis [51]. Thirdly, hyaluronan can influence cell behavior
through its interaction with its cell surface receptors, namely,
CD44 or receptor for hyaluronan-mediated motility, and
initiate intracellular signaling [52, 53].
HMW hyaluronan undergo constant turnover during
the daily maintenance of basement membranes, and its
degradation into small, nonbiologically active fragments is
rapidly removed from the body by the liver. In chronic in-
flammation, elevated serum levels of hyaluronan and its
deposition at sites of injury are often observed. The ac-
cumulation of hyaluronan in tissues has been shown to ex-
acerbate inflammatory processes. Fragmentation of ECM
components often occurs during tissue injury, and these frag-
ments possess functional properties that are distinct from
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Table 1: Functions of native hyaluronan and its fragments during tissue homeostasis and inflammation.
HMW hyaluronan LMW hyaluronan
Contributes to the protective role of the glycocalyx, acts as a
lubricant
Induces chemokine and cytokine secretion by infiltrating,
mesothelial, renal tubular epithelial and endothelial cells
Transportation and distribution of plasma proteins Induces phosphorylation of signaling pathways, for example, MAPK
Contributes to water balance and regulation of tissue hydration Induces cell migration, for example, tumor cells
Contributes to tissue integrity and maintenance of epithelial cell
phenotype
Induces cell proliferation in chondrocytes, endothelial cells, and
fibroblasts
Protects against tissue damage by scavenging free radicals Activates NFκB
Protects against apoptosis Induces nitric oxide synthase
Antiangiogenic Promotes angiogenesis
Inhibits phagocytosis by monocytes and macrophages Increases matrix protein synthesis, for example, collagen type I
Anti-inflammatory, can inhibit activation of inflammatory cells Increases transcription of matrix metalloproteinases
Promotes cell quiescence Suppresses cell death and apoptosis in cell culture
Immunosuppressive (prevents ligand binding to surface receptors) Induces heat-shock protein expression
LMW hyaluronan: ranges from 4 to 40 saccharide units.
their parent molecule [46]. The clearance of ECM fragments
is therefore imperative for the resolution of tissue injury.
Independent researchers have suggested that LMW hyaluro-
nan may deposit in inflamed tissues consequent to their de
novo synthesis or through the depolymerization of native
hyaluronan following increased activity of hyaluronidase
or reactive oxygen species [46, 54, 55]. Unlike native hya-
luronan, hyaluronan fragments have been shown to pro-
mote angiogenesis, induce multiple signaling cascades, and
increase cell proliferation, cytokine secretion, matrix metal-
loproteinase (MMP) activity, and matrix protein synthesis in
murine models of lung disease or cultured mesothelial and
endothelial cells, keratinocytes, macrophages, and dendritic
cells [46, 56–62]. Proinflammatory cytokines and profibrotic
growth factors have been shown to increase synthesis of both
HMW and LMW hyaluronan in various cell types [63–66].
Table 1 summarizes the distinct roles of HMW and LMW
hyaluronan under physiologic and inflammatory conditions.
Despite numerous articles highlighting the inflammatory
properties of LMW hyaluronan in vitro or ex vivo, one
must take note that reports detailing the actual appearance
of LMW hyaluronan in tissues undergoing inflammation
are limited [67]. The lack of antibodies that distinguishes
between native HA and its fragments may, in part, contribute
to this paucity of data, and therefore in-depth biochemical
methodologies are warranted to provide evidence of their
presence at sites of inflammation and tissue injury.
4. The Role of Hyaluronan in the Maintenance
of the Normal Peritoneal Membrane
In the healthy individual, a thin film of fluid is found on the
surface of mesothelial cells, which serves as a lubricant for
the peritoneal viscera that protects the mesothelial surface
from abrasions and adhesions. This fluid constitutes the
glycocalyx and contains a number of macromolecules that
include lipoproteins, phospholipids, and hyaluronan. The
integrity of the glycocalyx is, in part, attributed to the
presence of HMW hyaluronan [68, 69]. The glycocalyx
contributes to the protective, nonadhesive nature of the
mesothelial cell surface and plays an important role in
cell-cell contact, tissue integrity and hydration, regulation
of inflammation, wound healing, and flow of nutrients
and growth factors across the peritoneal membrane [70].
The luminal surface of mesothelial cells is endowed with
microvilli [28]. Microvilli entrap water and serous exudates,
which protect the delicate surface of mesothelial cells from
frictional damage [27]. Microvilli allows mesothelial cells
to sense their microenvironment and also functions to
entrap bacteria thereby preventing infection. The density
of microvilli on regenerating mesothelial cells may vary
and is dependent on the anionic charge of the glycocalyx
[28]. Recent studies have demonstrated that the presence
of hyaluronan in the glycocalyx of MCF-7 cells is essential
for the formation of microvilli and that the length of these
protrusions is dependent on HAS activity and the rate
of hyaluronan synthesis [71]. The removal of hyaluronan
from microvilli following treatment with hyaluronidase is
accompanied by their retraction from the cell surface [71].
The synthesis of microvilli on mesothelial cells has not been
fully investigated, but it is possible that it is regulated by
hyaluronan as observed in MCF-7 cells. The presence of
microvilli on the surface of mesothelial cells can increase
the surface area of the peritoneal membrane available for
peritoneal transport from 2m2 to 40m2. A reduction in the
number of microvilli on mesothelial cells would therefore
have a profound effect on peritoneal function and transport.
The peritoneal mesothelium provides the first line of
defense against bacteria, chemical, or surgical insult. It is
therefore essential that following injury and denudation,
rapid restoration of the mesothelial monolayer takes place.
The mechanism through which the normal mesothelium is
restored is controversial and has been suggested to involve
centripedal migration of mesothelial cells as observed in the
squamous epithelium, exfoliation of healthy mesothelial cells
from neighboring sites which settle on the denuded area,
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free-floating reserve cells, submesothelial and bone-marrow-
derived precursor cells, and macrophage transformation [27,
72–79].
We and others have shown that mesothelial cells synthe-
size large quantities of hyaluronan that is secreted into their
microenvironment or can be found on the mesothelial cell
surface as a major constituent of the mesothelial glycocalyx
[16–18, 63, 80]. Hyaluronan plays an essential role in
peritoneal homeostasis, but changes in hyaluronan synthesis
and its interaction with its cell surface receptors can have
a profound effect on cell function. Increased hyaluronan
synthesis in mesothelial cells is associated with increased cell
migration, proliferation, and phenotypic changes [47, 81].
Using an established in vitro model of wound healing, we
have demonstrated that, followingmechanical denudation of
the mesothelial monolayer, repopulation of the monolayer
is mediated by the migration of mesothelial cells from the
leading edge of the wound into the denuded area [8]. This
process is accompanied by a loss of cell-cell contact at the
wound margin and induction of epithelial-to-mesenchymal
transdifferentiation (EMT), a reversible process that bestows
upon mesothelial cells a migratory, invasive fibroblastic phe-
notype and is accompanied by the dissolution of intercel-
lular junctions, loss of cell polarity, reorganization of the
cytoskeleton and focal adhesion components, and increased
synthesis of matrix proteins and hyaluronan, the latter
observed predominantly in migratory, elongated mesothelial
cells [8, 82]. The increase in hyaluronan synthesis during
remesothelialization was mediated through an increase in
HAS II mRNA expression with a concomitant decrease in
HAS III expression [8]. The ability of mesothelial cells to
manifest features of mesenchyme underscores the plasticity
property of these cells. The early phase of remesothelial-
ization was dependent primarily on cell migration, and
cell proliferation was observed during the latter part of
mesothelial replenishment. Mesothelial cells reassumed their
cobblestone, epithelial morphology once the monolayer
was reestablished and cell-cell contact restored, and this
was associated with a decrease in hyaluronan synthesis.
The importance of hyaluronan in mesothelial regeneration
was highlighted in separate studies, whereby the rate of
remesothelialization increased with rising concentration of
exogenous hyaluronan added to the denuded monolayer [8].
The significance of hyaluronan in reepithelialization and
wound healing was corroborated in the skin and shown to
depend on its interaction with its cell surface receptor CD44,
since interference of hyaluronan-CD44 interaction resulted
in delayed wound healing and defective skin elasticity [83].
5. TheEffect of PDonHyaluronanSynthesis and
Mesothelial Cell Function
Acute inflammation is a defense mechanism that has evolved
in response to tissue injury. It is characterized by increased
vascular permeability, cell infiltration to sites of injury,
release of inflammatory mediators by both resident and
infiltrating cells, and increased matrix turnover. Although
inflammation may initiate temporary tissue damage, sub-
sequent reparative processes promote the resolution of in-
flammation. Repeated insult to the peritoneal membrane as
observed in PD, however, disturbs the reparative process,
which results in chronic inflammation and subsequent des-
truction of the tissue.
5.1. PD Increases Hyaluronan Synthesis in Mesothelial Cells.
Hyaluronan is often used as a surrogate marker of inflam-
mation. We and others have demonstrated that low levels
of hyaluronan can be detected in dialysis effluent obtained
from noninfected PD patients and that these levels are
significantly increased in PD patients with peritonitis [16,
80]. Our observation that serum hyaluronan levels did not
differ between noninfected and infected PD patients and
that dialysate hyaluronan levels are almost 2- and 10-folds
higher that the corresponding serum levels in noninfected
and infected PD patients, respectively, would imply that
local production accounts for the hyaluronan detected in
PD fluid [16]. Biochemical analysis of hyaluronan purified
from noninfected and infected dialysis effluent showed it
to be of a HMW with a hydrodynamic size of 0.75 as de-
termined by Sephacryl-S1000 gel filtration [16]. We have
demonstrated that over 90% of hyaluronan synthesized by
cultured mesothelial cells under basal conditions is secreted
into their culture medium and its molecular weight is iden-
tical to that detected in PD fluid. This together with our
observation that both noninfected and infected PD fluids can
induce de novo synthesis of hyaluronan in mesothelial cells
would indicate that mesothelial cells are a likely source of
dialysate hyaluronan [16].
The molecular weight of hyaluronan retained on the sur-
face of mesothelial cells is larger than that secreted suggest-
ing partial depolymerization of the parent molecule as it
is released from the plasma membrane [16]. Once released
by mesothelial cells, hyaluronan appears stable and does
not further undergo fragmentation in the peritoneal cavity
despite ongoing peritoneal inflammation [16]. Increased
synthesis of hyaluronan in mesothelial cells during perito-
nitis is attributed to pro-inflammatory cytokines and growth
factors, in particular IL-1β [63, 80]. The inability to detect
hyaluronan fragments in spent PD fluids corroborates pre-
vious reports that LMW hyaluronan is not observed in situ
[84].
5.2. Altered Hyaluronan Content in the Mesothelial Glycocalyx
during PD. Commencement of PD in patients with end-
stage renal disease is associated with the dilution of the gly-
cocalyx’s constituents and their subsequent removal from the
peritoneal cavity with each exchange of PD fluid. A loss of the
protective glycocalyx surrounding mesothelial cells would
imply increased susceptibility of these cells to the detri-
mental effect of PD fluids. Studies have demonstrated that
disruption of the glycocalyx in human smooth muscle cells
using hyaluronan oligosaccharides inhibited cell migration
and proliferation and resulted in a marked change to their
morphology with the appearance of a flattened, more adher-
ence phenotype [51]. We and others have demonstrated that
PD fluid or its constituents can induce senescence in cultured
mesothelial cells and such cells can also be isolated from
spent PD fluid [26, 85–88]. Mesothelial cells with a senescent
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phenotype have reduced cell proliferation, are more adherent
to their substrate, and have increased fibrogenic properties
[87, 89, 90]. Furthermore, ultrastructural studies have high-
lighted a reduction in the number and length of microvilli
on these senescent cells compared to normal mesothelial cells
[90]. Since hyaluronan plays a crucial role in the formation
of microvilli, the unphysiological concentration of glucose
in PD solutions could exert its harmful effects through
altered hyaluronan synthesis and/or increased release from
the mesothelial glycocalyx into the peritoneal cavity, and
such effects would result in phenotypic changes and altered
cellular functions. The observed increase in hyaluronan levels
in dialysis effluent may in part be attributed to its release
from the mesothelial glycocalyx. In line with this suggestion,
hyperglycemia has been shown to reduce the volume of
the endothelial glycocalyx in diabetic patients, which was
associated with increased release of glycocalyx constituents
into the circulation and perturbed vascular functions [91].
The importance of hyaluronan in maintaining the struc-
tural and functional integrity of the peritoneum during PD
is highlighted in rat models of PD in which hyaluronan sup-
plementation significantly reduced peritoneal inflammation,
preserved the structural integrity of the peritoneum, and
improved ultrafiltration and membrane transport functions
[92–96]. Furthermore, in vitro studies whereby peritoneal
mesothelial cells were incubated with exogenous HMW
hyaluronan resulted in reduced secretion of fibronectin
and inflammatory mediators, thus confirming the anti-
inflammatory and antifibrotic properties of hyaluronan [97].
Hyaluronan supplementationmay replenish peritoneal levels
of hyaluronan and decrease the hydraulic conductivity of
the submesothelium, thereby preventing PD fluid absorption
[95, 98].
5.3. PD Increases Submesothelial Expression of Hyaluronan.
In a recent study, Osada et al. assessed the intraperitoneal
expression of hyaluronan in PD patients and healthy controls
[99]. These researchers observed a weak expression of
hyaluronan in the peritoneum of healthy subjects, whilst
increased expression of hyaluronan was noted in the sub-
mesothelium of uremic patients who had just entered the
PD program. Submesothelial expression of hyaluronan was
further increased in chronic PD patients and also in patients
who had developed peritonitis [99]. Although Osada et
al. did not investigate the mechanism that resulted in an
increase in intraperitoneal expression of hyaluronan, it may
be attributed to increased levels of proinflammatory and
fibrotic cytokines in the peritoneal cavity [14, 100–102] since
PDGF, IL-1β, IL-6, TNF-α, and TGF-β1 have all been shown
to increase hyaluronan secretion in cultured mesothelial
cells and fibroblasts [18, 63]. Overexpression of hyaluronan
is indicative of a breakdown in the fine balance between
synthesis and degradation. These researchers did not provide
any details of hyaluronan expression in the mesothelium,
the molecular weight of hyaluronan expressed within the
submesothelium, nor HAS activity in the peritoneum, and
we were unable to determine whether peritoneal specimens
used in their study were partially or completely devoid of
a mesothelium, a phenomenon frequently observed in PD
patients [6]. Changes in the submesothelium has been shown
to precede the loss of the mesothelium in PD patients and is
associated with peritoneal fibrosis and vasculopathy [6]. Is it
therefore possible for increased submesothelial expression of
hyaluronan to induce mesothelial denudation and peritoneal
fibrosis? In an attempt to answer this, one must first explore
the mechanism that upholds the integrity of an epithelial
monolayer and the consequences of altered cell phenotype
and subsequent pathologic EMT, with particular focus on
hyaluronan in these processes.
5.4. Putative Role of Hyaluronan in EMT and Peritoneal
Fibrosis. The expression of E-cadherin is a cardinal feature of
epithelial monolayers [103, 104]. A loss of E-cadherin at the
intercellular junctions is strongly associated with epithelial
dedifferentiation, phenotypic alterations, and induction of
EMT. E-cadherin is a calcium-dependent transmembrane
glycoprotein that is localized at the basolateral membrane
in adherens junctions and endows epithelial cells with their
apicobasolateral polarity [104, 105]. E-cadherin is a suppres-
sor of CD44-hyaluronan interactions and has been shown
to prevent epithelial dedifferentiation and subsequent EMT
[106]. A balance between E-cadherin and CD44-hyaluronan
is therefore essential to maintain normal epithelial cell inte-
gity and function. In the setting of PD, decreased expression
of ZO-1, E-cadherin, and β-catenin is observed in cultured
mesothelial cells upon stimulation with elevated glucose
concentration [33]. A reduction in E-cadherin expression in
mesothelial cells would indicate a loss of the cells’ ability
to suppress hyaluronan expression. We have previously de-
monstrated that increased hyaluronan expression is critical
for inducing EMT in mesothelial cells during wound healing
and tissue repair but, once the mesothelial monolayer is
replenished, hyaluronan levels return to constitutive levels
[8]. The persistent increase in intraperitoneal expression of
hyaluronan during PD would suggest that mesothelial cells
are sustained in an activated fibroblastic phenotype (patho-
logic EMT) and mesenchymal-to-epithelial transdifferenti-
ation is inhibited. Increased production of hyaluronan and
its accumulation in the ECM has been shown to diminish
contact inhibition in nontransformed rat 3Y1 cells [52],
thereby underscoring the importance of hyaluronan in phys-
iologic and pathologic EMT. Under physiological conditions,
epithelial cells will undergo apoptosis if they are detached
from their substratum [107]. However, epithelial cells that
have undergone EMT have developed specific mechanisms
that allow them to survive as anchorage-independent cells
without cell-cell interactions [53]. Emerging evidence sug-
gests that hyaluronan triggers numerous signaling pathways
that promote cell survival of transdifferentiated cells [108].
The acquisition of amigratory and invasive phenotype allows
mesothelial cells to migrate into the submesothelium follow-
ing the disruption of the basementmembrane, which is made
possible by the increased production and activity of MMPs
[86]. Transdifferentiated mesothelial cells adopt a more
fibrogenic characteristic that allows them to contribute to the
thickening of the submesothelium and subsequent peritoneal
fibrosis [109, 110]. The migration of mesothelial cells into
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Figure 1: Changes to hyaluronan synthesis during PD alter mesothelial cell functions. The mesothelium contributes to peritoneal
homeostasis. Under physiologic conditions, mesothelial cells secrete HMW hyaluronan which is the main constituent of the glycocalyx. The
glycocalyx surrounds the apical surface of mesothelial cells and provides a protective barrier against abrasion, and a slippery, nonadhesion
surface for intracoelomic movement (1). Mesothelial cells participate in tissue repair and in the induction and resolution of peritoneal
inflammation through their ability to synthesize cytokines and growth factors that are secreted into the peritoneal cavity (2). Mesothelial cells
also synthesize matrix proteins which provide a substratum onto which mesothelial cells adhere (2). Mesothelial cells facilitate the transport
of fluids and solutes across the peritoneal membrane (3), are the first line of defense against bacterial peritonitis (4), and can maintain a
chemotactic gradient to assist in leukocyte infiltration (5) during bacterial, chemical, or surgical insult. Changes to the peritoneum following
the initiation of PD. Constant exposure of the peritoneal membrane to bioincompatible PD solution results in either a reduction of the
glycocalyx volume (6) or its complete depletion from the surface of mesothelial cells. Changes in the content of hyaluronan in the peritoneum
can induce morphologic and phenotypic changes to mesothelial cells that include reduced length and density of microvilli on the surface of
mesothelial cells (7), generation of senescent cells (8), and frequent denudation of themesothelium (9), thereby allowing PD solutions to leak
into the submesothelium causing peritoneal injury (10). Activation of both immune cells and mesothelial cells further increases synthesis
of cytokines and growth factors (11), which exacerbates peritoneal inflammation, fibrogenesis, and increases submesothelial expression of
HMW hyaluronan (12). Activation of mesothelial cells induces EMT (13), breakdown of the basement membrane, and their migration into
the submesothelium. Communication of activated mesothelial cells with peritoneal fibroblasts and endothelial cells may provoke further
inflammatory and fibrotic processes in the submesothelium resulting ultimately in peritoneal fibrosis.
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the submesothelium may also contribute to the denudation
of the mesothelium, mediated in part through increased
bioactivation of TGF-β1, a key mediator of tissue fibrosis
[110]. An inability to restore the mesothelial monolayer
is associated with unfavorable structural and functional
changes in the peritoneal membrane of PD patients [6].
What is the functional role of hyaluronan in the subme-
sothelium? Unfortunately, it is not possible to provide direct
evidence of its contributing role to peritoneal fibrosis due to
a lack of research in this area. Nevertheless, by extrapolating
data from other studies, one may conceive that sustained
increase in intraperitoneal expression of hyaluronan pro-
longs pathologic EMT and inflammation leading ultimately
to peritoneal fibrosis. In this respect, high-molecular-weight
hyaluronan has been demonstrated to induce Snail2 in
NIH-3T3 mouse fibroblasts, which endow the cells with an
increased invasive activity [111]. HMW hyaluronan has also
been shown to upregulate MMP activity in lymphoma cell
lines and metastatic tumor cells through the prior induction
of NFκB [112]. Accumulation of hyaluronan in keratocytes
mediates TGF-β1 induction of α-smooth muscle actin and
matrix protein synthesis [62]. That hyaluronan can augment
fibrotic processes is corroborated by the observation that
gene silencing of HAS II or removal of hyaluronan by
digestion with hyaluronidase inhibited TGF-β1-induced α-
smooth muscle and fibronectin mRNA [62]. Taken together,
these data would suggest that overexpression of hyaluronan
plays a critical role in the induction of cell activation and
tissue fibrosis, its transformation from a molecule that can
exert a beneficial effect on tissue homeostasis to one that
mediates tissue injury is dependent largely on its tissue
concentration, localization, and molecular weight.
6. Hyaluronan as a Surrogate Marker for
Peritoneal Inflammation
Deleterious changes to the structural integrity of the peri-
toneal membrane are often associated with a loss of dialytic
potential in PD patients, which can lead to technique
failure. Thickening of the submesothelium is a consistent
observation in PD patients [6]. Studies have highlighted
that the bioincompatible nature of PD solutions is a major
instigator of EMT and peritoneal fibrosis. Although exam-
ination of peritoneal biopsies allows clinicians to monitor
morphologic changes in the peritoneal membrane with time
on PD, this method is invasive and cannot be performed
frequently. The measurement of pro-/anti-inflammatory and
fibrotic markers in dialysate effluent has provided researchers
with a noninvasive method to indirectly assess the physical
condition of the peritoneum with time. The measurement
of hyaluronan in spent PD solutions provides researchers
and clinicians with an indication of the degree of peritoneal
inflammation with time and treatment regimens. In a
quest to preserve the functional properties of the peritoneal
membrane, new PD solutions have been developed that use
amino acids or icodextrin as the osmotic agent instead of
glucose or the partial substitution of lactate with bicarbonate
[113–115]. The use of alternative PD fluids is associated
with a reduction of proinflammatory mediators such as
hyaluronan and a concomitant increase in CA125 levels, a
marker of mesothelial cell mass and peritoneal membrane
integrity [101, 102, 116, 117].
The levels of hyaluronan in biological fluids are a good
indicator of numerous diseases and inflammation. Stud-
ies have demonstrated strong correlations between serum
hyaluronan levels and the degree of impaired renal function
[118, 119]. Increased serum levels of hyaluronan have also
been shown to predict mortality and morbidity in PD
patients [120], whereas dialysate levels of hyaluronan can
predict survival in PD patients [121].
7. Conclusion
PD is an effective modality of renal replacement therapy for
patients with end-stage renal disease, but, due to the bio-
incompatible nature of PD solutions, a chronic inflammatory
response is generally observed within the peritoneal cavity,
which jeopardizes the structural and functional integrity
of the peritoneal membrane. Structural changes begin with
the modification of the mesothelial monolayer, with a loss
of microvilli, widening of the intracellular gap junctions,
loss of E-cadherin, the adoption of a migratory, fibroblastic
phenotype, and induction of EMT, which progress to
peritoneal fibrosis. Studies have demonstrated that each of
these processes is regulated or influenced by hyaluronan. It is
intriguing that different molecular weights or concentrations
of hyaluronan could result in distinct effects on biolog-
ical processes. Pathologic changes in the peritoneum are
attributed solely to HMW hyaluronan and not its fragments.
Our knowledge of the contributing role of hyaluronan in
peritoneal homeostasis and pathology, its interaction with
its binding proteins, and how its synthesis is modulated
during inflammation and fibrosis is far from complete. It is
envisaged that, with time, we may unravel the many mys-
teries of hyaluronan, which will allow us to devise novel
therapeutic interventions to preserve the structural and func-
tional integrity of the peritoneum and thereby improv-
ing patient survival on PD.
Figure 1 shows a schematic diagram that details the cur-
rent understanding of how hyaluronan protects the perito-
neum during peritoneal homeostasis (upper panel) and how
changes to its level and localization can mediate changes
to mesothelial phenotype, function, and induce peritoneal
injury in the setting of PD (lower panel).
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